Live Analyst Rating Changes 1505 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Andy Hsieh
WB
Andy Hsieh
William Blair
Wall Street Analyst
★☆☆☆☆
#2383
on 13Foresight · ranked by our own returns
26%
Success Rate
-11.9%
Average Return
5 of 19 calls profitable · -16.0% vs benchmark
📈 Across the calls we could measure, roughly 26% of Andy Hsieh's ratings turned a profit when each position was held for 1 year — averaging -11.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

103 Buy 47 Hold 0 Sell
Andy's Stock Coverage 22 ratings · 2026-06-18
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
VKTX
Viking Therapeutics
 Jun 09, 2026 BUY Strong Buy
+141.0% avg upside
30 analysts
 — +1.4%
GPCR
Structure Therapeutics, Inc. Sponsored ADR
 Jun 08, 2026 BUY Strong Buy
+129.9% avg upside
17 analysts
 — ·
TNYA
Tenaya Therapeutics
 Jun 03, 2026 BUY Strong Buy
+1328.2% avg upside
11 analysts
 — ·
LNTH
Lantheus
 Jun 03, 2026 BUY Strong Buy
-27.6% avg upside
20 analysts
 — +4.4%
CRDF
Cardiff Oncology
 Jun 03, 2026 BUY Strong Buy
+739.6% avg upside
18 analysts
 — ·
CRBP
Corbus Pharmaceuticals
 Jun 01, 2026 BUY Strong Buy
+346.7% avg upside
20 analysts
 — ·
KLRA
Kailera Therapeutics, Inc.
 May 27, 2026 BUY Strong Buy
+103.9% avg upside
5 analysts
 — ·
AARD
Aardvark Therapeutics, Inc.
 May 15, 2026 BUY Buy
+399.2% avg upside
12 analysts
 — +0.0%
PYXS
Pyxis Oncology
 May 14, 2026 HOLD Strong Buy
+255.0% avg upside
13 analysts
 — -14.0%
AVIR
Atea Pharmaceuticals
 May 13, 2026 BUY Buy
+50.1% avg upside
6 analysts
 — -1.8%
ALT
Altimmune
 May 13, 2026 HOLD Strong Buy
+935.0% avg upside
19 analysts
 — -4.0%
KYNB
Kyntra Bio
 May 12, 2026 HOLD Buy
+358.3% avg upside
14 analysts
 — ·
SKYE
Skye Bioscience
 May 12, 2026 BUY Strong Buy
+1327.3% avg upside
9 analysts
 — +0.0%
BIOA
BioAge Labs, Inc.
 May 11, 2026 HOLD Strong Buy
+145.1% avg upside
9 analysts
 — -2.8%
NKTR
Nektar Therapeutics
 May 07, 2026 BUY Buy
+18.4% avg upside
25 analysts
 — -26.9%
EXEL
Exelixis
 May 06, 2026 BUY Strong Buy
-21.4% avg upside
33 analysts
$44.00
16.14% Downside
 +9.1%
AKTS
Aktis Oncology, Inc.
 Apr 29, 2026 BUY Strong Buy
+32.6% avg upside
8 analysts
$32.00
36.07% Upside
 ·
ZLDPF
Zealand Pharma
 Mar 06, 2026 HOLD Buy
+92.5% avg upside
11 analysts
 — ·
BRNS
Barinthus Biotherapeutics
 Aug 07, 2025 BUY Strong Buy
+517.5% avg upside
5 analysts
 — -51.8%
ATNM
Actinium Pharmaceuticals
 Dec 22, 2023 HOLD Strong Buy
+638.6% avg upside
11 analysts
 — -75.7%
BYSI
Beyondspring
 Dec 01, 2021 HOLD Hold
+406.1% avg upside
8 analysts
 — -88.4%
GILD
Gilead Sciences
 Feb 12, 2019 BUY Strong Buy
-5.6% avg upside
66 analysts
 — +6.3%
🔒 17 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Andy Hsieh — Frequently Asked Questions
How accurate are Andy Hsieh's stock ratings?
Based on the calls 13Foresight could measure, about 26% of Andy's ratings were profitable over a one-year hold, with an average return of -11.9% per rating, or -16.0% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Andy ranked on 13Foresight?
Andy Hsieh is currently ranked #2383 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Andy cover?
Andy most recently has ratings on VKTX, GPCR, TNYA, LNTH, CRDF, CRBP, KLRA, AARD, PYXS, AVIR, ALT, KYNB and 10 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.